INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss Buys 10,000 Shares

INmune Bio, Inc. (NASDAQ:INMB) CFO David J. Moss bought 10,000 shares of INmune Bio stock in a transaction that occurred on Monday, September 30th. The shares were acquired at an average price of $5.29 per share, with a total value of $52,900.00. Following the acquisition, the chief financial officer now directly owns 1,285,869 shares of the company’s stock, valued at approximately $6,802,247.01. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

INmune Bio Price Performance

NASDAQ INMB traded up $0.17 on Monday, hitting $5.39. 399,282 shares of the stock were exchanged, compared to its average volume of 153,766. The business’s fifty day moving average is $6.73 and its 200 day moving average is $8.75. INmune Bio, Inc. has a 52 week low of $4.81 and a 52 week high of $14.74. The company has a market capitalization of $106.62 million, a PE ratio of -2.75 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative net margin of 26,333.59% and a negative return on equity of 103.56%.

Hedge Funds Weigh In On INmune Bio

Several large investors have recently modified their holdings of INMB. CVI Holdings LLC bought a new position in shares of INmune Bio in the second quarter valued at about $5,260,000. Marshall Wace LLP increased its position in INmune Bio by 332.1% during the second quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after acquiring an additional 89,091 shares during the period. Bank of New York Mellon Corp increased its position in INmune Bio by 124.6% during the second quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after acquiring an additional 32,511 shares during the period. Rhumbline Advisers bought a new position in INmune Bio during the second quarter worth about $121,000. Finally, Westside Investment Management Inc. increased its position in INmune Bio by 31.8% during the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock worth $400,000 after acquiring an additional 10,950 shares during the period. 12.72% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have issued reports on INMB. Scotiabank began coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price target on the stock. Raymond James began coverage on shares of INmune Bio in a research report on Friday. They set an “outperform” rating and a $18.00 price target on the stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.